Receptos, Inc.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
The company has seen 2 negative revisions in the past 1 month, while its Zacks Consensus Estimate of a loss widened over the same period, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward to see if this recent move higher can last.
Receptos currently has a Zacks Rank #4 (Sell) while its Earnings ESP is 0.00%.
Other attractive players in the healthcare industry include Illumina Inc. (NASDAQ: ILMN) and Gilead Sciences Inc. (NASDAQ: GILD), carrying a Zacks Rank #1 (Strong Buy) and Ariad Pharmaceuticals Inc. (NASDAQ: ARIA) with a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
RECEPTOS INC (NASDAQ: RCPT): Free Stock Analysis Report
ILLUMINA INC (NASDAQ: ILMN): Free Stock Analysis Report
GILEAD SCIENCES (NASDAQ: GILD): Free Stock Analysis Report
ARIAD PHARMA (NASDAQ: ARIA): Free Stock Analysis Report
To read this article on Zacks.com click here.